Jiří Vencovský

researcher

Born 1953-11-16

Jiří Vencovský is …
instance of (P31):
humanQ5

External links are
P1280CONOR.SI ID70615907
P691NL CR AUT IDjo20000080529
P496ORCID iD0000-0002-0851-0713
P3368Prabook ID415153
P3829Publons author ID2119530
P1053ResearcherIDG-6094-2017
P1153Scopus author ID55941728700
P214VIAF ID84117517

P1343described by sourceMedvikQ99413897
P108employerCharles UniversityQ31519
Revmatologický ústavQ30281927
P734family nameVencovskýQ51914367
VencovskýQ51914367
VencovskýQ51914367
P735given nameJiříQ168563
JiříQ168563
P1412languages spoken, written or signedCzechQ9056
P106occupationresearcherQ1650915
immunologistQ12119633
rheumatologistQ5997943
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q57752711Q57752711
Q57752738Q57752738
Q121914761Dermatomyositis a polymyositis
Q122006850Farmakoterapie revmatických onemocnění
Q122029420Revmatologie
Q57752724119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands
Q565060422010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
Q341306712010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Q584906732016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects
Q468157622016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri
Q388491482016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology
Q479241812016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology
Q388491442016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri
Q476532762017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
Q476994982017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.
Q35554739A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
Q37604518A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
Q40327635A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Q51060022A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
Q57752360A1.48 Enhanced expression of CD11c on non-classical CD16+peripheral blood monocytes in early rheumatoid arthritis
Q57752369A3.29 Micro-RNA molecules are clearly involved in pathogenesis of idiopathic inflammatory myopathy
Q57752371A3.30 Plasma level of HSP70 protein is increased in czech patients with idiopathic inflammatory myopathy
Q57752332AB0009 Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech Patients
Q57752346AB0163 Comprehensive Analysis of Circulating Mirnas in Patients with Axial Spondyloarthritis
Q47674978Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
Q54381969Acute cricopharyngeal obstruction in dermatomyositis.
Q57752526Adipokine profile is modulated in subcutaneous adipose tissue by TNF inhibitors in patients with rheumatoid arthritis
Q57752460Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis
Q57752651Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis
Q38834515Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study
Q38021653Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature
Q57752454Anti-Ro52 epitope mapping in inflammatory myopathies
Q43498070Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.
Q38208567Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations
Q34237586Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.
Q41824468Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.
Q57536946Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies
Q57752590CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis
Q38818188Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis
Q48480707Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
Q36045392Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Q104613975Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis
Q58614815Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study
Q41257255Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus
Q37934396Clinical trials roundup in idiopathic inflammatory myopathies.
Q57752845Clinical-morphological correlation of polymyositis and dermatomyositis
Q52816251Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al.
Q57752274Corrigendum to “CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis” [Clin. Immunol. 136 (2010) 139–147]
Q57752356Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis
Q30839061Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort
Q35617658Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.
Q52893591Delays in assessment of patients with rheumatoid arthritis: variations across Europe.
Q42098903Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups
Q36335887Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.
Q52814958Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo.
Q36424500Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
Q57752304Dr. Vencovsky, et al reply
Q57245349EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
Q54145043Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study.
Q37172815Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
Q37172820Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
Q57752593Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage
Q57752656Endogenous HLA–DR–restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint
Q37939700European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
Q36205767Expression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis.
Q34528042Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies
Q57752335FRI0520 Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies
Q92354292Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
Q57752597Genetic variation in promoter sequence of B cell-activating factor gene is associated with increased risk of myositis development
Q34490287Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.
Q37601815Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders
Q35752908Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies.
Q57752812HETEROGENEITY OF DISEASE PHENOTYPE IN MONOZYGOTIC TWINS CONCORDANT FOR RHEUMATOID ARTHRITIS
Q57752790Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis
Q30876263High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort
Q57752758Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis
Q57752480IFN signature is associated with autoantibody profiles in patients with myositis
Q57752786IL-10 Gene Promoter Polymorphisms in Rheumatoid Arthritis: SHORT REPORT
Q57752602Immune cell-derived microparticles in polymyositis/dermatomyositis
Q39021882Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum
Q57752797Immunoglobulin Variable Region (IgV) Gene Expression in Rheumatoid Factors from Monozygotic Twins with Rheumatoid Arthritis
Q57752524Immunolocalization of protein-bound 3-nitrotyrosine in inflammatory myopathies
Q50758762Immunological investigation in children with juvenile chronic arthritis.
Q43204037Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis
Q46483118Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Q57806415Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients
Q40799107Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience.
Q51730918Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
Q42706490Inflammatory myopathy associated with statins: report of three cases
Q36020198Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study
Q35882730Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.
Q38702140Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis.
Q57752293Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease
Q36084879International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis
Q39138840International collaboration including patients is essential to develop new therapies for patients with myositis
Q35179618International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.
Q39745186Interrater reliability and aspects of validity of the myositis damage index
Q47095910Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.
Q57752499Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis
Q38644438MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies
Q57752609Metastasis-Promoting protein S100A4 (MTS1) upregulates production of proinflammatory cytokines via TLR-4
Q44918219Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis.
Q57752504Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis
Q36960767MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis
Q57752546Modulation of subcutaneous adipose tissue adipokines by TNF- blockade therapy in patients with inflammatory arthritides
Q50983253Molecular markers of systemic autoimmune disorders: the expression of MHC-located HSP70 genes is significantly associated with autoimmunity development.
Q57752818Monozygotic Rheumatoid Arthritis Twin Pairs Express Similar Levels of Conserved Immunoglobulin V Gene in Polyclonal Rheumatoid Factors Irrespective of Disease Status
Q57752613Myositis associated autoantibodies detected using a novel recombinant protein blotting: clinical associations
Q45233460New findings on the pathogenesis of rheumatoid arthritis
Q57752510No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis
Q57752516Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis
Q57752365OP0235 Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations
Q57752319OP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheu
Q57752299OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
Q42353372Opportunities and challenges in rheumatology research in Central Europe
Q36041246Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis
Q36588160Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases
Q57752615Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis
Q57752552Potential role of S100A4 in an immune response of rheumatoid arthritis
Q42956746Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate
Q44147825Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study
Q40636094Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria.
Q57752308Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis
Q56957893Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Q35962863Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis
Q34440026Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies
Q45208119Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents
Q57752665Quantiferon-TB Gold test in screening for latent tuberculosis before and during antitumour necrosis factor treatment
Q57752823RHEUMATOID FACTORS AND GERMLINE GENES IN RHEUMATOID ARTHRITIS: EVIDENCE OF AN INTRINSIC B-LYMPHOCYTE DEFECT?
Q57752669Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment
Q46663336Recommendations of Czech Rheumatological Society for the treatment of rheumatoid arthritis. Efficacy and treatment strategies
Q41497288Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.
Q57752642Reliability and validity of the myositis disease activity assessment tool
Q36245955Resistin in idiopathic inflammatory myopathies
Q48091996Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al.
Q52816457Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al.
Q52815225Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences' by Shah.
Q52817973Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al.
Q48457754Rheumatoid arthritis: the goal rather than the health-care provider is key.
Q57752324SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1
Q57752376SAT0565 The Expression and Regulation of the Argonaute Protein Family Member PIWIL4 in RA
Q34061733Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus
Q36188496Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission
Q36067062Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
Q90575845Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis
Q57752559Serum levels of IFN- do not correlate with disease activity in patients with dermatomyositis/polymyositis
Q57752562Serum levels of interferon do not correlate with disease activity in patients with dermatomyositis/polymyositis
Q36321563Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study
Q91532373Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study
Q91314854Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry
Q41500940Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis.
Q48248837Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis
Q57752350THU0528 Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis
Q26765038The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
Q38601741The EuroMyositis registry: an international collaborative tool to facilitate myositis research.
Q54305524The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Q45011283The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
Q41862536The expression profile of miR-23b is not altered in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies
Q57752566The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1*03 risk allele
Q36183786The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
Q44832774The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels.
Q57752573The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy
Q57752577The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies
Q34560305The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies
Q57752382The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis
Q57752677The role of MRI in the assessment of polymyositis and dermatomyositis
Q38099557The role of resistin in inflammatory myopathies.
Q46198003The significance of antibodies to cyclic citrullinated peptide, antikeratin antibodies, anti-perinuclear factor, rheumatoid factor isotypes and HLA shared epitope in prediction of erosive disease in early rheumatoid arthritis patients.
Q57752391The two mRNA transcription variants of the B-cell activating factor are differentially expressed, but in a stable ratio
Q57752735Therapeutic strategies in polymyositis and dermatomyositis
Q38246832Therapy of myositis: biological and physical
Q37763782Treatment-resistant inflammatory myopathy
Q57752753Tumour necrosis factor α G→A −238 and G→A −308 polymorphisms in juvenile idiopathic arthritis
Q45141851Use of pulsed steroid therapy in active rheumatoid arthritis
Q57752623Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis
Q57752703[How can the autoantibody detection help in the diagnostics and evaluation of autoimmune rheumatic diseases?]
Q53758852[Immune mediated necrotizing myopathy associated with statin treatment].
Q57752803[Practical results of monitoring pregnancy in women with systemic lupus erythematosus]
Q57752808[Rheumatoid pericarditis: correlation with immunologic parameters]
Q57752682[Rheumatologic manifestations in diabetes]

Search more.